Example: Heart Attack

Search clinical trials for: Fludarabine

Total 1952 results

NCT05888493

Not yet recruiting

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (LEDA)

Follicular Lymphoma (FL)
NCT05885464

Recruiting

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

Lymphoblastic Lymphoma | Lymphoblastic Leukemia | T-Cell Lymphoblastic Leukemia/Lymphoma
NCT05886491

Not yet recruiting

A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia
NCT05884333

Recruiting

Cord Blood Transplant in Adults With Blood Cancers

Non-Hodgkin's Lymphoma | Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukemia (ALL) | Myeloproliferative Disorder | Acute Myelogenous Leukemia (AML) | Chronic Myelogenous Leukemia (CML)
NCT05883449

Not yet recruiting

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203)

Peripheral T Cell Lymphoma | Relapsed or Refractory Hodgkin Lymphoma
NCT05881525

Recruiting

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Advanced Solid Tumors
NCT05880043

Recruiting

A Study of GIC-102 (Allogeneic Natural Killer Cells) in Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, and Multiple Myeloma

Advanced Solid Tumors | Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Non-Hodgkin Lymphoma
NCT05877599

Not yet recruiting

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Breast Cancer | Pancreatic Adenocarcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Colorectal Carcinoma | Other Solid Tumors
NCT05878184

Recruiting

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma
NCT05876832

Not yet recruiting

A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

Acute Myeloid Leukemia With FLT3/ITD Mutation
NCT05873712

Not yet recruiting

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory Transformed Chronic Lymphocytic Leukemia | Refractory Transformed
NCT05870995

Recruiting

Chemotherapy CLAGE-Ven Sequential With Reduced Dose of MBF for Refractory Acute Myelodi Leukemia

Refractory Leukemia
NCT05869955

Not yet recruiting

A Study of CC-97540 in Participants With Severe, Refractory Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus, Systemic
NCT05868915

Recruiting

HV-101 for Patients With Advanced Solid Tumors

Advanced Solid Tumors
NCT05862324

Not yet recruiting

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3)

Metastatic Solid Tumor
NCT05849662

Not yet recruiting

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Neurofibromatosis 1 | JMML | Leukemia, Juvenile Myelomonocytic | JCML | CBL Syndrome
NCT05848999

Recruiting

UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Mesothelin-positive Advanced Malignant Solid Tumors
NCT05849207

Not yet recruiting

Post-Transplant Cyclophosphamide in Patients Aged >/=70 Years Undergoing Haploidentical Transplant (GeriBMT)

Hematologic Malignancies
NCT05832515

Recruiting

AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis

Multiple Sclerosis
NCT05831033

Not yet recruiting

Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients With Advanced Solid Tumors

Solid Tumor
NCT05807932

Not yet recruiting

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia
NCT05807659

Recruiting

Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies

Myeloid Malignancies
NCT05805605

Recruiting

Allo HSCT Using RIC and PTCy for Hematological Diseases

Follicular Lymphoma | Myelodysplastic Syndromes | Leukemia, Myeloid | Myelofibrosis | Burkitt Lymphoma | Marginal Zone Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia
NCT05797233

Not yet recruiting

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia | B-Cell Chronic Lymphocytic Leukemia
NCT05798533

Recruiting

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

Solid Tumor
NCT05798546

Recruiting

Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)

Solid Tumor
NCT05787574

Recruiting

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

Immune System Diseases | Autoimmune Lymphoproliferative | Primary Immune Regulatory Disorder
NCT05787535

Not yet recruiting

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

Cervical Cancer | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Cancer | Anal Carcinoma | Vagina Tumor | Carcinoma of Penis | Carcinoma of Vulva
NCT05780879

Not yet recruiting

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia
NCT05779930

Not yet recruiting

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

Acute Lymphoblastic Leukemia, in Relapse | B Cell Leukemia | B-cell Non Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphoblastic Leukemia With Failed Remission
NCT05775666

Not yet recruiting

UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Solid Tumor
NCT05776407

Not yet recruiting

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Refractory or Relapsed B Cell Lymphoma
NCT05768529

Recruiting

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05767359

Recruiting

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Multiple Myeloma | Smoldering Multiple Myeloma
NCT05761171

Not yet recruiting

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage

Search clinical trials for: Fludarabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations